Skip to main content
Have a personal or library account? Click to login
Specific Associations Between Clinical Signs, Immune Cells, Disease Genetic Background and Burden in a Group of Patients with B-Cell Chronic Lymphocytic Leukemia Cover

Specific Associations Between Clinical Signs, Immune Cells, Disease Genetic Background and Burden in a Group of Patients with B-Cell Chronic Lymphocytic Leukemia

Open Access
|Mar 2014

References

  1. 1. Grigore GE, Dascalescu A, Zlei M, Ivanov IC, Danaila C, Petreus T, et al. Rai stage-related changes within T/ NK cell populations from B-CLL patients. Rev Romana Med Lab. 2013;21(3):321-31. DOI: 10.2478/rrlm-2013-0032
  2. 2. D’Arena G, Guariglia R, La Rocca F, Trino S, Condelli V, De Martino L, et al. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. Clin Dev Immunol. 2013:730131. DOI: 10.1155/2013/730131
  3. 3. Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. ASH Education Program Book. 2009;2009(1):440-9.
  4. 4. Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J et al. Human peripheral blood B-cell compartments: A crossroad in B-cell traffic. Cytometry Part B: Clinical Cytometry. 2010;78(S1):S47-S60. DOI: 10.1002/cyto.b.20547
  5. 5. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010 Jan;10(1):37-50. DOI: 10.1038/nrc2764
  6. 6. Davids MS, Burger JA. Cell trafficking in chronic lymphocytic leukemia. Open J Hematol. 2012;3(S1).
  7. 7. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. British journal of haematology. 2003;123(3):380-8. DOI: 10.1046/j.1365-2141.2003.04679.x
  8. 8. Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. European Journal of Immunology. 2002;32(5):1403-13. DOI: 10.1002/1521-4141(200205)32:5<1403::AID-IMMU1403> 3.0.CO;2-Y
  9. 9. Fabris S, Scarciolla O, Morabito F, Cifarelli RA, Dininno C, Cutrona G, et al. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in Chronic lymphocytic leukemia: A comparative study. Genes, Chromosomes and Cancer. 2011;50(9):726-34. DOI: 10.1002/gcc.20894
  10. 10. Deutsch AJA, Steinbauer E, Hofmann NA, Strunk D, Gerlza T, Beham-Schmid C, et al. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma. Mod Pathol. 2013 Feb;26(2):182-94.
  11. 11. Han T, Abdel-Motal UM, Chang D-K, Sui J, Muvaffak A, Campbell J, et al. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous t-cell lymphoma. PloS one. 2012;7(9):e44455. DOI: 10.1371/journal. pone.0044455
  12. 12. Chang D-K, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge RC, et al. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Molecular Cancer Therapeutics. 2012;11(11):2451-61. DOI: 10.1158/1535-7163.MCT-12-0278
  13. 13. Ishida T, Ishii T, Inagaki A, Yano H, Kusumoto S, Ri M, et al. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia. 2006;20(12):2162-8. DOI: 10.1038/sj.leu.2404415
  14. 14. Al-haidari Amr A., Syk I, Jirström K, Thorlacius H. CCR4 mediates CCL17 (TARC)-induced migration of human colon cancer cells via RhoA/Rho-kinase signaling. Int J Colorectal Dis. 2013 Nov 1;28(11):1479-87. DOI: 10.1007/s00384-013-1712-y
  15. 15. Li J-Y, Ou Z-L, Yu S-J, Gu X-L, Yang C, Chen A-X et al. The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. Breast cancer research and treatment. 2012;131(3):837-48. DOI: 10.1007/s10549-011-1502-6
  16. 16. Tsujikawa T, Yaguchi T, Ohmura G, Ohta S, Kobayashi A, Kawamura N, et al. Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma. Int J Cancer. 2013 Jun 15;132(12):2755-66. DOI: 10.1002/ijc.27966
  17. 17. Mahadevan D, Choi J, Cooke L, Simons B, Riley C, Klinkhammer T, et al. Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/ PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration. Hum Genomics Proteomics. 2009;2009:453634. DOI: 10.4061/2009/453634
  18. 18. Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O, et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev. 2013 Feb;24(1):41-9. DOI: 10.1016/j.cytogfr.2012.08.007
  19. 19. Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O’Malley FP, et al. Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry. Clinical Cancer Research. 2013;19(2):336-46. DOI: 10.1158/1078-0432.CCR-11-3314
  20. 20. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110(9):3316-25. DOI: 10.1182/ blood-2007-05-089409
  21. 21. Okada T, Ngo VN, Ekland EH, Förster R, Lipp M, Littman DR, et al. Chemokine requirements for B cell entry to lymph nodes and Peyer’s patches. The Journal of experimental medicine. 2002;196(1):65-75. DOI: 10.1084/jem.20020201
  22. 22. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118(13):3470-8. DOI: 10.1182/blood-2011-06-275610
  23. 23. Nagira M, Imai T, Yoshida R, Takagi S, Iwasaki M, Baba M, et al. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. European Journal of Immunology. 1998;28(5):1516-23. DOI: 10.1002/ (SICI)1521-4141(199805)28:05<1516::AID-IMMU1516> 3.0.CO;2-J
  24. 24. Kunkel EJ, Butcher EC. Plasma-cell homing. Nature Reviews Immunology. 2003;3(10):822-9. DOI: 10.1038/nri1203
  25. 25. Nannini PR, Borge M, Mikolaitis VC, Abreu C, Morande PE, Zanetti SR, et al. CCR4 expression in a case of cutaneous Richter’s transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL) and in CLL patients with no skin manifestations. European Journal of Haematology. 2011;87(1):80-6. DOI: 10.1111/j.1600-0609.2011.01613.x
  26. 26. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, et al. Rules of chemokine receptor association with T cell polarization in vivo. Journal of Clinical Investigation. 2001;108(9):1331-9. DOI: 10.1172/ JCI200113543
  27. 27. Cózar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, et al. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunology, Immunotherapy. 2005;54(9):858-66. DOI: 10.1007/s00262-004-0646-1
  28. 28. Svensson H, Olofsson V, Lundin S, Yakkala C, Björck S, Börjesson L, et al. Accumulation of CCR4+ CTLA-4hi FOXP3+ CD25hi regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells. PloS one. 2012;7(2):e30695. DOI: 10.1371/journal.pone.0030695
  29. 29. Monserrat J, Ángel Sánchez M, de Paz R, Díaz D, Mur S, Reyes E, et al. Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients. Cytometry Part B: Clinical Cytometry. 2013. DOI: 10.1002/cytob.21120
  30. 30. Ocana E, Delgado-Perez L, Campos-Caro A, Munoz J, Paz A, Franco R, et al. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica. 2007;92(3):349-56. DOI: 10.3324/haematol. 10649
  31. 31. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000;95(2):627-32.
  32. 32. Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica. 2006;91(11):1489-97.
  33. 33. Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M, et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. Journal of Clinical Investigation. 1999;104(1):115-21. DOI: 10.1172/JCI7335
  34. 34. Wong S, Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leukemia & lymphoma. 2004;45(12):2491-6. DOI: 10.1080/10428190410001723449
  35. 35. Cambien B, Karimdjee B, Richard-Fiardo P, Bziouech H, Barthel R, Millet M, et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. British journal of cancer. 2009;100(11):1755-64. DOI: 10.1038/sj.bjc.6605078
  36. 36. Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. International Journal of Cancer. 2009;125(11):2586-94. DOI: 10.1002/ijc.24665
  37. 37. López-Giral S, Quintana NE, Cabrerizo M, Alfonso- Pérez M, Sala-Valdés M, de Soria VGG, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. Journal of leukocyte biology. 2004;76(2):462-71. DOI: 10.1189/jlb.1203652
  38. 38. Reif K, Ekland EH, Ohl L, Nakano H, Lipp M, Förster R, et al. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature. 2002;416(6876):94-9. DOI: 10.1038/416094a
  39. 39. Cha Z, Zang Y, Guo H, Rechlic JR, Olasnova LM, Gu H, et al. Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia. Tumour Biol. 2013 Dec;34(6):3579-85. DOI: 10.1007/s13277-013-0937-2
  40. 40. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nature immunology. 2001;2(12):1126-32. DOI: 10.1038/ni735
  41. 41. Jadidi-Niaragh F, Yousefi M, Memarian A, Hojjat-Farsangi M, Khoshnoodi J, Razavi SM, et al. Increased Frequency of CD8+ and CD4+ Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression. Cancer investigation. 2013;31(2):121-31. DOI: 10.3109/07357907.2012.756110
  42. 42. Scrivener S, Goddard R, Kaminski E, Prentice A. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leukemia & lymphoma. 2003;44(3):383-9. DOI: 10.1080/1042819021000029993
  43. 43. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007;110(9):3352-9. DOI: 10.1182/ blood-2007-04-083832
  44. 44. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer research. 2009;69(9):4001-9. DOI: 10.1158/0008-5472.CAN-08-4173
  45. 45. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-74. DOI: 10.1182/ blood-2010-05-284984
  46. 46. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, et al. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010;115(19):3916-22. DOI: 10.1182/ blood-2009-10-249367
  47. 47. Ouillette P, Collins R, Shakhan S, Li J, Li C, Shedden K, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clinical Cancer Research. 2011;17(21):6778-90. DOI: 10.1158/1078-0432.CCR-11-0785
  48. 48. Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S, et al. NOTCH1 mutations in+ 12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of+ 12 CLL. Haematologica. 2012;97(3):437-41. DOI: 10.3324/haematol.2011.060129
DOI: https://doi.org/10.2478/rrlm-2014-0004 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624 (formerly 2284-5623)
Language: English, Romanian
Page range: 79 - 92
Published on: Mar 25, 2014
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services

© 2014 Georgiana Emilia Grigore, Iuliu C. Ivanov, Mihaela Zlei, Angela Dăscălescu, Roxana Popescu, Tudor Petreuș, Eugen Carasevici, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons License.